Loading…
Dianthus Therapeutics, Inc. is projected to rise to $148.47 by 2027, a +32% move from its current price of $112.64. DNTH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $108.98 | $112.71 | $116.57 | +0.06% |
| Aug 2 | $107.53 | $112.78 | $118.28 | +0.13% |
| Aug 3 | $106.46 | $112.85 | $119.63 | +0.19% |
| Aug 4 | $105.57 | $112.92 | $120.79 | +0.25% |
| Aug 5 | $104.80 | $113.00 | $121.84 | +0.32% |
| Aug 6 | $104.11 | $113.07 | $122.79 | +0.38% |
| Aug 7 | $103.49 | $113.14 | $123.68 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $103.49 | $113.14 | $123.68 | +0.44% |
| Week 2 | $100.18 | $113.64 | $128.90 | +0.89% |
| Week 3 | $97.81 | $114.14 | $133.19 | +1.33% |
| Week 4 | $95.92 | $114.64 | $137.01 | +1.78% |
| Week 5 | $94.34 | $115.15 | $140.54 | +2.23% |
| Week 6 | $92.97 | $115.66 | $143.88 | +2.68% |
| Week 7 | $91.76 | $116.17 | $147.06 | +3.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, is a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein.
The company also develops DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (BDCA2) to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
DNTH is the stock name for Dianthus Therapeutics, Inc. Its current price is $105.60 and its market cap is $5.77B, with a market rank of 1224. This places DNTH among mid-cap biotechnology peers with a focus on autoimmune disease therapies.
A major floor 36.4% below — a decisive break under it would weaken the trend.
The nearest floor, 27.3% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 18.2% above — clearing it would confirm fresh momentum.
Key DNTH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DNTH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $105.34 | Buy | $106.49 | Buy |
| MA 10 | $104.66 | Buy | $104.39 | Buy |
| MA 20 | $101.04 | Buy | $101.09 | Buy |
| MA 50 | $92.24 | Buy | $94.48 | Buy |
| MA 100 | $88.94 | Buy | $85.74 | Buy |
| MA 200 | $66.28 | Buy | $71.14 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.95 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 212.34 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.34 | Buy |
| ROC (12) | 11.22 | Buy |
| Bollinger %B (20,2) | 1.13 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.63 | Buy |
| Awesome (5,34) | 10.01 | Buy |
| Ultimate (7,14,28) | 66.50 | Neutral |
| Momentum (10) | 17.29 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 105.91 | Buy |
| ADX (14) | 19.25 | Neutral |
| ATR (14) | 3.25 | Info |
The near-term technical picture shows a bullish tilt overall, with a 30-day range of $83.95 to $132.84. The sentiment is BULLISH, and the RSI(14) is 60, with the price trading above the SMA50 of $88.95 and the SMA200 of $63.19. A near-term support level sits at $76.42 and resistance at $105.60.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $36.20 | $112.64 | $158.37 | 0% | Neutral | |
| $115.88 | $148.47 | $202.60 | +32% | Bullish | |
| $158.27 | $210.16 | $299.94 | +87% | Bullish | |
| $192.69 | $263.57 | $389.45 | +134% | Bullish | |
| $214.95 | $301.87 | $459.14 | +168% | Bullish | |
| $239.15 | $344.04 | $536.61 | +205% | Bullish | |
| $256.20 | $376.96 | $601.28 | +235% | Bullish | |
| $273.48 | $411.02 | $669.02 | +265% | Bullish | |
| $290.26 | $445.16 | $738.17 | +295% | Bullish | |
| $373.75 | $584.47 | $985.97 | +419% | Bullish | |
| $499.80 | $854.72 | $1,548.76 | +659% | Bullish | |
| $1,165.06 | $2,335.64 | $4,690.95 | +19.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $36.20 | $112.64 | $131.61 | +0.00% |
| August 2026 | $99.87 | $117.79 | $142.60 | +4.57% |
| September 2026 | $100.10 | $119.30 | $146.80 | +1.28% |
| October 2026 | $96.37 | $115.80 | $144.35 | -2.93% |
| November 2026 | $97.43 | $117.89 | $148.48 | +1.80% |
| December 2026 | $102.30 | $124.57 | $158.37 | +5.66% |
Click any year to see its month-by-month DNTH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Dianthus Therapeutics, Inc.'s 2026 outlook centres on $112.64, within a $36.20 to $158.37 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, DNTH could reach as high as $202.60, with a base case around $148.47 and support toward $115.88 — roughly +32% from $112.64. Momentum favours further upside here.
Expect DNTH to range from $158.27 to $299.94 through 2028. The $210.16 average target implies a +87% move from current prices. That is up +42% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The DNTH price prediction for 2029 points to an average of $263.57 (low $192.69, high $389.45) — a potential gain of +134% on today's $112.64. Momentum favours further upside here.
In 2030, DNTH is projected to trade between $214.95 and $459.14, averaging $301.87 — a potential gain of +168% from today's $112.64. That is up +15% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Dianthus Therapeutics, Inc.'s 2031 outlook centres on $344.04, within a $239.15 to $536.61 range. That is up +14% on the projected 2030 average. That marks a +205% change versus current levels. Momentum favours further upside here.
By 2032, DNTH could reach as high as $601.28, with a base case around $376.96 and support toward $256.20 — roughly +235% from $112.64. Buyers look set to stay in control over this stretch.
Expect DNTH to range from $273.48 to $669.02 through 2033. The $411.02 average target implies a +265% move from current prices. That is up +9% on the projected 2032 average. Momentum favours further upside here.
The DNTH price prediction for 2034 points to an average of $445.16 (low $290.26, high $738.17) — a potential gain of +295% on today's $112.64. Buyers look set to stay in control over this stretch.
In 2035, DNTH is projected to trade between $373.75 and $985.97, averaging $584.47 — a potential gain of +419% from today's $112.64. That is up +31% on the projected 2034 average. Momentum favours further upside here.
Dianthus Therapeutics, Inc.'s 2040 outlook centres on $854.72, within a $499.80 to $1,548.76 range. That is up +46% on the projected 2035 average. That marks a +659% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, DNTH could reach as high as $4,690.95, with a base case around $2,335.64 and support toward $1,165.06 — roughly +19.7x from $112.64. Momentum favours further upside here.
Investing $1,000 in DNTH today (≈ 8.877841 DNTH) could be worth
$20,735.48
+$19,735.48 (+1974%) by 2050 · US Dollar
Based on the average projected DNTH price of $2,335.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DNTHwould be worth at today's price.
$1,000 invested in DNTH on Jul 30, 2025 (≈ 48.076925 DNTH) would be worth
$5,415.38
+$4,415.38 (+441.5%) today · 5.42× · US Dollar
Based on a DNTH entry price of $20.8 vs. today's $112.64.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $104.79 | $1,074.91 | +7.5% |
| 1 month ago | $97.48 | $1,155.52 | +15.6% |
| 3 months ago | $87.42 | $1,288.49 | +28.8% |
| 6 months ago | $53.39 | $2,109.76 | +111.0% |
| 1 year ago | $20.8 | $5,415.38 | +441.5% |
| All time (5.0y) ago | $113.76 | $990.15 | -1.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DNTH forecast.
Our base-case forecast reaches $230.00 around 2029.
Implied market cap at $230.00: $12.57B
The multi-year forecast shows strong upside potential, with the 2030 average price at $282.80 and a max of $433.96, yielding a 167.8% ROI. By 2040, the average price is projected to $824.20 with a max of $1,512.02 and a 680.5% ROI. By 2050, the average price could reach $2,235.13, with a max of $4,553.64 and a 2016.6% ROI.
All forecasts are bullish during these years, highlighting substantial upside potential alongside inherent uncertainty in future market conditions.
Tap a question to reveal the answer.
2030 min $199.70, avg $282.80, max $433.96; ROI 167.8%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising avg prices and high ROI (e.g., 2027 avg $137.78, ROI 30.5%; 2050 avg $2,235.13, ROI 2016.6%). These are estimates and not guarantees.
Yes. The forecast maxs indicate DNTH could reach beyond $1,000, with a max of $1,512.02 by 2040 and $4,553.64 by 2050.
2040 avg $824.20; 2050 avg $2,235.13.
Dianthus Therapeutics, Inc. Community Discussion
0Share your Dianthus Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.